Bisphosphonates | Brighter Hope Foundation Glossary
What Are Bisphosphonates?
Bisphosphonates are medications that affect how calcium is deposited in the body. They are commonly used to treat diseases involving calcium buildup in bones or abnormal calcification in bones, such as osteoporosis.
In rare diseases like Generalized Arterial Calcification of Infancy (GACI), bisphosphonates have been studied because they can mimic the effects of pyrophosphate, a natural compound that helps prevent abnormal calcium deposits. Unlike many conditions treated with bisphosphonates, GACI primarily involves calcification in arteries and soft tissues, rather than the bones themselves.
Historically, bisphosphonates were used as a treatment option for infants diagnosed with GACI in an effort to slow the progression of abnormal calcification.
Why Bisphosphonates Were Used in GACI
GACI is typically caused by mutations in the ENPP1 or ABCC6 genes. These mutations disrupt the body’s ability to produce enough pyrophosphate (PPi), a molecule that normally helps prevent unwanted mineral deposits.
Without enough pyrophosphate, calcium can accumulate in places where it should not, particularly in blood vessels and soft tissues. This abnormal calcification can cause narrowing of arteries and serious cardiovascular complications early in life.
Because bisphosphonates have a chemical structure similar to pyrophosphate, doctors explored whether they could help reduce the abnormal calcification seen in infants with GACI.
The Critical Role of Early Treatment
Research has shown that bisphosphonate therapy may only be effective if treatment begins extremely early in life.
Studies suggest that the medication must be started within the first seven days after birth to have the greatest potential benefit. Beginning treatment during this narrow window may help slow the progression of abnormal calcium deposits in arteries and other tissues.
Because GACI can progress rapidly in newborns, early diagnosis and prompt medical evaluation are essential.
The most important takeaway from current research is that bisphosphonates may help reduce calcification only when treatment begins very early—ideally within the first week of life.
Why Bisphosphonates Are Used Less Often Today
Today, very few babies are treated with bisphosphonates.
Advances in research have led to the development of therapies that more directly target the underlying cause of GACI. Clinical trial medications are now generally considered a better option when a child is eligible for treatment.
Eligibility typically requires confirmation of biallelic mutations in the ENPP1 or ABCC6 gene, which are known to cause GACI and related disorders.
When these mutations are identified, targeted therapies being studied in clinical trials may provide a more effective approach to managing the disease.
For this reason, bisphosphonates are now used far less frequently than they were in earlier stages of GACI treatment research.
Learn More About GACI and Related Conditions
Brighter Hope Foundation provides trusted information and resources for families, caregivers, and healthcare professionals seeking to better understand these rare calcification disorders.
Explore additional resources:
